Paradigm Biopharmaceuticals Ltd has released a press release.
Consistent pain reduction and improvement in function data
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Response to ASX Query
- R&D Investor Presentation
- Paradigm receives postive feedback from FDA type c meeting
- Paradigm Provides Phase 3 Clinical Trial Update
- First patient dosed in mps-i phase 2 clinical trial
Later from Paradigm Biopharmaceuticals
- Paradigm delivers IND to US FDA for Pivotal OA Program
- Paradigm and Bene Execute New Collaboration Agreement
- Paradigm doses first participant in Synovial Fluid Trial
- Paradigm provides ind application update
- Paradigm achieves first revenue
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals